GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (NAS:LNTH) » Definitions » FCF Yield %

Lantheus Holdings (Lantheus Holdings) FCF Yield % : 5.76 (As of Apr. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Lantheus Holdings's Trailing 12-Month Free Cash Flow is $259 Mil, and Market Cap is $4,494 Mil. Therefore, Lantheus Holdings's FCF Yield % for today is 5.76%.

The historical rank and industry rank for Lantheus Holdings's FCF Yield % or its related term are showing as below:

LNTH' s FCF Yield % Range Over the Past 10 Years
Min: -6.49   Med: 5.4   Max: 23.75
Current: 5.76


During the past 13 years, the highest FCF Yield % of Lantheus Holdings was 23.75%. The lowest was -6.49%. And the median was 5.40%.

LNTH's FCF Yield % is ranked better than
81.57% of 1080 companies
in the Drug Manufacturers industry
Industry Median: -0.65 vs LNTH: 5.76

Lantheus Holdings's FCF Margin % for the quarter that ended in Dec. 2023 was 28.31%.


Lantheus Holdings FCF Yield % Historical Data

The historical data trend for Lantheus Holdings's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantheus Holdings FCF Yield % Chart

Lantheus Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.24 0.43 2.13 7.66 6.09

Lantheus Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.70 7.05 -2.99 8.59 9.44

Competitive Comparison of Lantheus Holdings's FCF Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lantheus Holdings's FCF Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Lantheus Holdings's FCF Yield % falls into.



Lantheus Holdings FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Lantheus Holdings's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=258.705 / 4248.488
=6.09%

Lantheus Holdings's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=100.218 * 4 / 4248.488
=9.44%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lantheus Holdings FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Lantheus Holdings FCF Yield % Related Terms

Thank you for viewing the detailed overview of Lantheus Holdings's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lantheus Holdings (Lantheus Holdings) Business Description

Traded in Other Exchanges
Address
201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Executives
Andrea Sabens officer: Chief Accounting Officer C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Marshall Robert J. Jr. officer: CFO and Treasurer C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Paul Blanchfield officer: Chief Commercial Officer C/O LANTHEUS HOLDINGS, INC., 331, NORTH BILLERICA MA 01862
Mary Anne Heino director, officer: CEO and President C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Daniel Niedzwiecki officer: See Remarks C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Etienne Montagut officer: See Remarks C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Sam R Leno director C/O BOSTON SCIENTIFIC CORPORATION, ONE BOSTON SCIENTIFIC PLACE, NATICK MA 01760
Brian A Markison director 501 FIFTH STREET, BRISTOL TN 37620
Jean-claude Provost officer: Chief Medical Officer C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON RD, SOUTH BUILDING, BEDFORD MA 01730
Julie Mchugh director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Gerard Ber director C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Carol Walker officer: Senior Vice President, Quality C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Ying Vivian Yao officer: Chief Human Resources Officer C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
John J. Bolla director C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862